A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 2046
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : UFH
Long Form : unfractionated heparin
No. Year Title Co-occurring Abbreviation
2022 Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients. MOCS
2022 Un-fractionated heparin counteracts the systemic inflammatory responses and multiple organ damages caused by endotoxaemia in sheep. LPS
2021 A Distinctive Approach to Venous Thromboembolism Treatment in a Pediatric, Hemodialysis Patient: A Case Report. HD, LMWH
2021 A Meta-Analysis of Extracorporeal Anticoagulants in Pediatric Continuous Kidney Replacement Therapy. CKRT, RCA
2021 A new anticoagulation strategy using recombinant human thrombomodulin in patients on veno-venous extracorporeal membrane oxygenation: a retrospective study. JAAM, rhTM, VV-ECMO
2021 A Severe Case of Idiosyncratic Hepatotoxicity with Unfractionated Heparin. POD
2021 A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. CI, COVID-19, HR, LMWH, LOS, OR, RCT
2021 A tale of two centers: Is low-molecular-weight heparin really superior for prevention of posttraumatic venous thromboembolism? DVT, LMWH, PE
2021 Activated Partial Thromboplastin Time Versus Anti-Factor Xa Monitoring of Heparin Anticoagulation in Adult Venoarterial Extracorporeal Membrane Oxygenation Patients. anti-Xa, APTT, ECMO
10  2021 Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. ACS, AKI, CI, KDIGO, OR, SCr
11  2021 Administration of Direct Oral Anticoagulant Immediately after Unfractionated Heparin Bolus for the Treatment of Intermediate-High-Risk Pulmonary Thromboembolism. CT, DOACs, VTE
12  2021 Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. CENTRAL, CI, LMWH, RCTs, RD, RR, VTE
13  2021 Anticoagulation strategies in continuous renal replacement therapy. CRRT, KDIGO, LMWH, RCA
14  2021 Antithrombin Dose Optimization in Extracorporeal Membrane Oxygenation in Infants. AT, AT, ECMO
15  2021 Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome-What is the evidence? CI, LMWH, RR
16  2021 APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation. anti-Xa, APTT
17  2021 Argatroban Anticoagulation for Adult Extracorporeal Membrane Oxygenation: A Systematic Review. ACT, APTT, AT, ECMO, HIT
18  2021 Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study. HIT, VV-ECMO
19  2021 Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world retrospective study. BMI, EF, MACCE, PCI, PPI
20  2021 Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice. ACS, GPIs, MACEs, NACEs, PCI, ST, TVR
21  2021 Cardiac transplantation after heparin-induced thrombocytopenia: A systematic review. HIT, OHT
22  2021 Cardiovascular and Respiratory Toxicity of Protamine Sulfate in Zebrafish and Rodent Models. HR, NO, PS
23  2021 Case Report: Heparin-induced thrombocytopenia during COVID-19 outbreak: the importance of scoring system in differentiating with sepsis-induced coagulopathy. ARDS, ER, HIT
24  2021 Comparison of Bivalirudin Versus Unfractionated Heparin for Anticoagulation in Adult Patients on Extracorporeal Membrane Oxygenation. ECMO, TR
25  2021 Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis. anti-Xa, APTT
26  2021 Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy. CAC, CI, LMWH, OR
27  2021 Comprehensive Intraprocedural Unfractionated Heparin Protocol During Catheter Ablation of Atrial Fibrillation in the Presence of Direct Oral Anticoagulants and Wide Spectrum of Body Mass Index. ACT, BMI, CA-AF, DOAC
28  2021 Conventional versus restricted anti-Xa-guided heparin protocol in adult patients undergoing extracorporeal membrane oxygenation. anti-Xa, ECMO, PRBC
29  2021 Diagnosis and treatment of disseminated intravascular coagulation in COVID-19 patients: a scoping review. COVID-19, DIC, ISTH, LMWH, SIC
30  2021 Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy. ACT, AF, PVI
31  2021 Effect of unfractionated heparin and low molecular weight heparin on the clotting of platelet-reduced whole blood: an in-vitro study utilizing thromboelastography. LMWH, TEG
32  2021 Effectiveness and Safety of Twice- Versus Thrice-Daily Subcutaneous Heparin for Venous Thromboembolism Prophylaxis at a Large Academic Medical Center. ISTH, TID, VTEP
33  2021 Effectiveness of fondaparinux vs unfractionated heparin following percutaneous coronary intervention in survivors of out-of-hospital cardiac arrest due to acute myocardial infarction. AMI, OHCA
34  2021 Effects of Bivalirudin and Unfractionated Heparin on Liver and Renal Function in Chinese Patients with Coronary Artery Disease Undergoing Coronary Angiography with/without Percutaneous Coronary Intervention. ALT, AST, CAG, CKD, eGFR, PCI
35  2021 Efficacy and Safety of Bivalirudin During Percutaneous Coronary Intervention in Chronic Total Occlusion: A Retrospective Study. CTO, MACEs, NACEs, PCI
36  2021 Efficacy and Safety of Heparinization before Deployment of Endograft for Blunt Traumatic Aortic Injury in Severely Injured Patients. BTAI, ISS, TEVAR
37  2021 Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors. DTIs, PCI
38  2021 Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients. ICU
39  2021 Evaluating the safety and efficacy of argatroban locking solution in the prevention of the dysfunction of haemodialysis central venous catheters: a study protocol for a randomized controlled trial. APTT, CVCs, HD
40  2021 Evaluation of a Multimodal Heparin Laboratory Monitoring Protocol in Adult Extracorporeal Membrane Oxygenation Patients. ACT, APTT, ATIII, ECMO
41  2021 Evaluation of Bivalirudin-Associated Major Adverse Cardiac and Hemorrhagic Events in Acute Coronary Syndrome Patients on Chronic Dialysis Following Percutaneous Coronary Intervention. ACS, MACE, PCI
42  2021 Evaluation of Enoxaparin for Inpatient Venous Thromboembolism Prophylaxis in End-Stage Renal Disease Patients on Hemodialysis. CRNMB, ESRD, HD, VTE
43  2021 Evaluation of the activated partial thromboplastin time and its influential factors in ischemic heart disease patients under heparin treatment. APTT, AUC, BUN, Cr, Hgb, PLS, PT
44  2021 Fondaparinux During Intra-Aortic Balloon Pump Counterpulsation in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. AMI, IABP, PCI
45  2021 From Activated Partial Thromboplastin Time to Antifactor Xa and Back AgainThe Evolution of Monitoring Unfractionated Heparin. anti-Xa, APTT
46  2021 Functional, proteomic and phenotypic in vitro studies evidence podocyte injury after chronic exposure to heparin. ---
47  2021 Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit. anti-Xa, APTT, ICU, LMWH
48  2021 Heparin for Vertebral Intraluminal Thrombus Causing Retroperitoneal Hemorrhage from Occult Renal Angiomyolipoma. AML
49  2021 Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. COVID-19, LMWH
50  2021 Heparin reversal by an oligoethylene glycol functionalized guanidinocalixarene. ---
51  2021 Heparin-Induced Bullous Hemorrhagic Dermatosis: A Report of an Exceptionally Exuberant Case and Literature Review. HBHD
52  2021 Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis. ACLF, LMWH, TAT, VTE
53  2021 Hepatic and renal cellular cytotoxic effects of heparin-coated superparamagnetic Iron oxide nanoparticles. LMWH, ROS, SCGE, SPIO
54  2021 Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial. NACE, TAVR
55  2021 Impact of Protocolized Pharmacist Intervention on Critical Activated Partial Thromboplastin Time Values With Heparin Infusions. APTT, BARC
56  2021 In vitro and invivo safety studies indicate that R15, a synthetic polyarginine peptide, could safely reverse the effects of unfractionated heparin. PS
57  2021 Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial. AKI, BARC, CKD, TAVR
58  2021 Interventions for preventing thrombosis in solid organ transplant recipients. CI, GRADE, RCTs, RR
59  2021 Low Molecular Weight Heparin Improves the Inflammatory State of Acute Sinusitis Rats Through Inhibiting the TLR4-MyD88-NF-kappaB Signaling Pathway. LMWH
60  2021 Low-Molecular Weight Heparin is Superior to Unfractionated Heparin for Elderly Trauma Patients. ISS, LMWH, VTE
61  2021 Management of Heparin-Induced Thrombocytopenia Using Plasmapharesis in Patients Undergoing HeartMate 3 Left Ventricular Assist Device. HIT, HM3
62  2021 Management of therapeutic unfractionated heparin in COVID-19 patients: A retrospective cohort study. aPTTs, CI, COVID-19
63  2021 Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA? ECMO
64  2021 Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation. anti-Xa, APTT, ECMO
65  2021 Outcomes of systemic anticoagulation with bivalirudin for Impella 5.0. BIV, HIT, IMP5, LVAD, tMCS, tPA
66  2021 Pediatric Mechanical Circulatory Support: Pathophysiology of Pediatric Hemostasis and Available Options. DTIs, ECMO, MCS, VADs
67  2021 Postprocedural Radial Artery Compression Time In Chronic AnticoaguLated patients using StatSeal: The PRACTICAL-SEAL study. NOACs, OAC
68  2021 Pragmatic Recommendations for the Management of Anticoagulation and Venous Thrombotic Disease for Hospitalized Patients with COVID-19 in Low- and Middle-Income Countries. GCS, IPC, LMICs, LMWH, VTE
69  2021 Prophylactic Low-Molecular-Weight Heparin Versus Unfractionated Heparin in Spine Surgery (PLUSS): A Pilot Matched Cohort Study. LMWH, PLUSS, VTE
70  2021 Protocol driven periprocedural anticoagulation for left atrial ablation. ACT, DOACs
71  2021 Reassessing the Pediatric Dosing Recommendations for Unfractionated Heparin Using Real-World Data: a Pharmacokinetic-Pharmacodynamic Modeling Approach. APTT, CL, PK/PD, Vd
72  2021 Red Algal Sulfated Galactan Binds and Protects Neural Cells from HIV-1 gp120 and Tat. BoSG, DXS, gp120, LvSF, Tat
73  2021 Rivaroxaban and apixaban for the treatment of suspected or confirmed heparin-induced thrombocytopenia. ASH, DOACs, HIT, LMWH
74  2021 Robust K-PD model for activated clotting time prediction and UFH dose individualisation during cardiopulmonary bypass. ACT, CPB, RMSE
75  2021 Running after Activated Clotting Time Values in Patients Receiving Direct Oral Anticoagulants: A Potentially Dangerous Race. Results from a Prospective Study in Atrial Fibrillation Catheter Ablation Procedures. ACT, AF, DOACs, VKA
76  2021 Safety and efficacy of Direct Oral Anticoagulants in cerebral venous thrombosis: A meta-analysis. CVT, DOACs, DVT, LMWH, PE, VKA
77  2021 Satisfactory outcome with low activated clotting time in extracorporeal membrane oxygenation. ACT, ECMO
78  2021 Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity. CIs, LMWH, MD, OR, RCTs, SMD
79  2021 Study of in vitro thrombin generation after neutralization of heparin. LMWH, NPP, TG
80  2021 Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia. LMWH, RBCs, S-NACH, SCD
81  2021 Systematic review of machine learning models for personalised dosing of heparin. aPTT, ML
82  2021 The effectiveness and safety of LMWH for preventing thrombosis in patients with spinal cord injury: a meta-analysis. LMWH
83  2021 The missing slope: paradoxical shortening of activated partial thromboplastin time in a patient on unfractionated heparin therapy. APTT, TT
84  2021 Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism. VTE
85  2021 Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases. FFP, GP, RBCs
86  2021 Thromboelastometry, Thromboelastography, and Conventional Tests to Assess Anticoagulation During Extracorporeal Support: A Prospective Observational Study. ACT, APTT, ECMO, R, min, ROTEM, TEG, VHA
87  2021 Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. ATE, COVID-19, CrCl, DD, ICU, LMWH, VTE
88  2021 UK national survey of anticoagulation in extra-corporeal photopheresis-Is it time for a UK consensus statement? ACD-A, ECP, UK
89  2021 Unfractionated and Low-Molecular-Weight Heparin for Bridging Patients with Left Ventricular Assist Device: An Event-Based Analysis. aHR, INR, LMWH, LVAD, NB
90  2021 Unfractionated Heparin Attenuated Histone-Induced Pulmonary Syndecan-1 Degradation in Mice: a Preliminary Study on the Roles of Heparinase Pathway. HPA
91  2021 Unfractionated Heparin Improves the Intestinal Microcirculation in a Canine Septic Shock Model. MAP
92  2021 Unfractionated Heparin TID Dosing Regimen Is Associated With a Lower Rate of Pulmonary Embolism When Compared With BID Dosing in Patients Undergoing Craniotomy. BID, DVT, ICH, PE, TID, VTE
93  2021 Using thermodynamic equilibrium models to predict the effect of antiviral agents on infectivity: Theoretical application to SARS-CoV-2 and other viruses. ACE2, HSV, Mpro, SARS-CoV-2, SGP, ZnOT
94  2021 Venous Thromboembolism Chemoprophylaxis in Trauma and Emergency General Surgery Patients: A Systematic Review. DOACs, EGS, LMWH, PRISMA, SCI, TBI, VTE
95  2021 Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period. CIs, DVT, HES, ICTRP, LMWH, PE, RRs, VTE
96  2021 Venous Thromboembolism Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis. LMWH, RCTs
97  2021 Viscoelastometry for detecting oral anticoagulants. CTEX-test, ECA-test, EX-test, FXa, IN-test, LMWH, RVV-test, TPA-test
98  2021 What Do We Know about Thromboprophylaxis and Its Monitoring in Critically Ill Patients? ICU, LMWH, VTE
99  2021 [Determination of sulfation degree of heparin and low molecular weight heparins by capillary electrophoresis]. CE, LMWHs, RSD, SD, T-SD
100  2021 [Treatment of sepsis-induced coagulopathy : Results of a Germany-wide survey in intensive care units]. COVID-19, ICU, LMWH, SIC, VTE